The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Experience shows that the handling of compendial and especially non-compendial and in-house reference standards and materials are often a challenge for OMCLs (Official Medicines Control Labs). The qualification of biological reference materials by the manufacturer and the OMCL has a direct influence on the final results of analytical tests and is thus of extremely high importance. The replacement of the reference vaccine’ case study highlights the difficulties encountered by the manufacturers and National Control Labs dealing with biological materials and methods(e.g. :In vivo, ELISA), and how to overcome them.
With increasing numbers of cell and gene therapy products in development and entering commercialization, more and more sponsors are facing a unique set of challenges of developing bioassays for cell and gene therapy products…
The number and diversity of biotherapeutic modalities continues to increase. These represent complex modalities such as peptide and peptide conjugates, antisense oligonucleotides, DNA- and RNA-based therapies, drug conjugates, as well as viral vector-based therapeutics…